Caribou Biosciences, Inc. (CRBU)
- Previous Close
3.9900 - Open
4.0000 - Bid 4.0600 x 100
- Ask 4.0700 x 200
- Day's Range
3.9900 - 4.2100 - 52 Week Range
3.4400 - 8.5900 - Volume
551,669 - Avg. Volume
1,620,724 - Market Cap (intraday)
366.677M - Beta (5Y Monthly) 2.47
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3800 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
20.00
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
cariboubio.comRecent News: CRBU
Performance Overview: CRBU
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CRBU
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CRBU
Valuation Measures
Market Cap
360.35M
Enterprise Value
58.64M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.54
Price/Book (mrq)
0.98
Enterprise Value/Revenue
1.70
Enterprise Value/EBITDA
-0.52
Financial Highlights
Profitability and Income Statement
Profit Margin
-296.05%
Return on Assets (ttm)
-18.00%
Return on Equity (ttm)
-30.50%
Revenue (ttm)
34.48M
Net Income Avi to Common (ttm)
-102.07M
Diluted EPS (ttm)
-1.3800
Balance Sheet and Cash Flow
Total Cash (mrq)
328.83M
Total Debt/Equity (mrq)
7.36%
Levered Free Cash Flow (ttm)
-64.36M